The Persistent Promise of Combining HGF/MET and EGFR Inhibition in Non-Small Cell Lung Cancer

被引：4
作者：
Chuang, Jody C. [1 ]
Neal, Joel W. [1 ]
机构：
[1] Stanford Univ, Dept Med, Div Oncol, Sch Med, Stanford, CA 94305 USA
来源：
CANCER | 2017年 / 123卷 / 15期
关键词：
TIVANTINIB ARQ 197; PHASE-III TRIAL; C-MET; PULMONARY ADENOCARCINOMA; 2ND-LINE TREATMENT; PLUS ERLOTINIB; ASIAN PATIENTS; GROWTH-FACTOR; DOUBLE-BLIND; OPEN-LABEL;
D O I：
10.1002/cncr.30718
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2798 / 2801
页数：4
相关论文
共 21 条
[1]  
Albain KS., 2005, J Clin Oncol, V23, P7014
[2]   First-In-Human Phase 1 Study of ABBV-399, an Antibody-Drug Conjugate (ADC) Targeting C-Met, in Patients with Non-Small Cell Lung Cancer (NSCLC) [J].
Angevin, Eric ;
Strickler, John ;
Weekes, Colin ;
Heist, Rebecca ;
Morgensztern, Daniel ;
Fan, Xiaolin ;
Olyaie, Ozzie ;
Motwani, Monica ;
Afar, Daniel ;
Naumovski, Louie ;
Kelly, Karen .
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) :S395-S396
[3]   Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study) [J].
Cicenas, Saulius ;
Geater, Sarayut Lucien ;
Petrov, Petar ;
Hotko, Yevgeniy ;
Hooper, Gregory ;
Xia, Fan ;
Mudie, Nadejda ;
Wu, Yi-Long .
LUNG CANCER, 2016, 102 :30-37
[4]   Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study [J].
Ciuleanu, Tudor ;
Stelmakh, Lilia ;
Cicenas, Saulius ;
Miliauskas, Skaidrius ;
Grigorescu, Alexandru Calin ;
Hillenbach, Carina ;
Johannsdottir, Hrefna Kristin ;
Klughammer, Barbara ;
Esteban Gonzalez, Emilio .
LANCET ONCOLOGY, 2012, 13 (03) :300-308
[5]   Targeting MET in Lung Cancer: Will Expectations Finally Be MET? [J].
Drilon, Alexander ;
Cappuzzo, Federico ;
Ignatius, Sai-Hong ;
Camidge, D. Ross .
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) :15-26
[6]   HGF-independent potentiation of EGFR action by c-Met [J].
Dulak, A. M. ;
Gubish, C. T. ;
Stabile, L. P. ;
Henry, C. ;
Siegfried, J. M. .
ONCOGENE, 2011, 30 (33) :3625-3635
[7]   Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial [J].
Garassino, Marina Chiara ;
Martelli, Olga ;
Broggini, Massimo ;
Farina, Gabriella ;
Veronese, Silvio ;
Rulli, Eliana ;
Bianchi, Filippo ;
Bettini, Anna ;
Longo, Flavia ;
Moscetti, Luca ;
Tomirotti, Maurizio ;
Marabese, Mirko ;
Ganzinelli, Monica ;
Lauricella, Calogero ;
Labianca, Roberto ;
Floriani, Irene ;
Giaccone, Giuseppe ;
Torri, Valter ;
Scanni, Alberto ;
Marsoni, Silvia .
LANCET ONCOLOGY, 2013, 14 (10) :981-988
[8]   Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition [J].
Katayama, Ryohei ;
Aoyama, Aki ;
Yamori, Takao ;
Qi, Jie ;
Oh-hara, Tomoko ;
Song, Youngchul ;
Engelman, Jeffrey A. ;
Fujita, Naoya .
CANCER RESEARCH, 2013, 73 (10) :3087-3096
[9]   Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA) [J].
Kawaguchi, Tomoya ;
Ando, Masahiko ;
Asami, Kazuhiro ;
Okano, Yoshio ;
Fukuda, Masaaki ;
Nakagawa, Hideyuki ;
Ibata, Hidenori ;
Kozuki, Toshiyuki ;
Endo, Takeo ;
Tamura, Atsuhisa ;
Kamimura, Mitsuhiro ;
Sakamoto, Kazuhiro ;
Yoshimi, Michihiro ;
Soejima, Yoshifumi ;
Tomizawa, Yoshio ;
Isa, Shun-ichi ;
Takada, Minoru ;
Saka, Hideo ;
Kubo, Akihito .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (18) :1902-1908
[10]   Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. [J].
Mok, Tony S. ;
Wu, Yi-Long ;
Thongprasert, Sumitra ;
Yang, Chih-Hsin ;
Chu, Da-Tong ;
Saijo, Nagahiro ;
Sunpaweravong, Patrapim ;
Han, Baohui ;
Margono, Benjamin ;
Ichinose, Yukito ;
Nishiwaki, Yutaka ;
Ohe, Yuichiro ;
Yang, Jin-Ji ;
Chewaskulyong, Busyamas ;
Jiang, Haiyi ;
Duffield, Emma L. ;
Watkins, Claire L. ;
Armour, Alison A. ;
Fukuoka, Masahiro .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (10) :947-957
123